Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;20 Suppl 1(0 1):S99-103.
doi: 10.1016/S1353-8020(13)70025-7.

Blood-based biomarkers for Parkinson's disease

Lama M Chahine  1 , Matthew B Stern, Alice Chen-Plotkin
Affiliations
Review

Blood-based biomarkers for Parkinson's disease

Lama M Chahine et al. Parkinsonism Relat Disord. 2014 Jan.

Abstract

There is a pressing need for biomarkers to diagnose Parkinson's disease (PD), assess disease severity, and prognosticate course. Various types of biologic specimens are potential candidates for identifying biomarkers--defined here as surrogate indicators of physiological or pathophysiological states--but blood has the advantage of being minimally invasive to obtain. There are, however, several challenges to identifying biomarkers in blood. Several candidate biomarkers identified in other diseases or in other types of biological fluids are being pursued as blood-based biomarkers in PD. In addition, unbiased discovery is underway using techniques including metabolomics, proteomics, and gene expression profiling. In this review, we summarize these techniques and discuss the challenges and successes of blood-based biomarker discovery in PD. Blood-based biomarkers that are discussed include α-synuclein, DJ-1, uric acid, epidermal growth factor, apolipoprotein-A1, and peripheral inflammatory markers.

Keywords: Blood-based biomarkers; Metabolomics; Parkinson's disease; Proteomics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002 Apr;125:861–70. - PubMed
    1. Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep. 2012;2:954. - PMC - PubMed
    1. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65:716–23. - PMC - PubMed
    1. Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, et al. Plasma apolipoprotein A1 as a biomarker for parkinson’s disease. Ann Neurol. 2013 Feb 27; - PMC - PubMed
    1. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011;69:655–63. - PMC - PubMed

Publication types